The Minnesota Department of Health (MDH) released its fifth report to the Legislature under the Prescription Drug Price Transparency Act, analyzing prescription drug pricing data reported through the first half of 2025 and assessing progress toward the Act’s transparency and cost management goals.

According to the report, prescription drug list prices continue to rise sharply, increasing an average of 58% from 2020–2025, including a 23% increase in the most recent year, far outpacing inflation.

High-cost therapeutic classes remain consistent, led by anti-inflammatory pain relievers, dermatological drugs, and anti-cancer medications. Manufacturer profits remain significant, with MDH estimating nearly $90 million in net profits tied to reported price increase drugs, including more than $2.5 million from patient cost sharing.

Continued drug price increases documented by MDH may prompt lawmakers to consider policy tools beyond transparency, with potential implications for pricing, reimbursement, and cost management strategies.